Allergan's Botox fine: Good marketing?

Allergan launched a marketing campaign to promote Botox for treating migraines, despite the fact that the FDA never gave it the green light. As punishment, the company received a bill for $600 million -- in the form of a fine and settlment -- from the Department of Justice.

Botox for Migraines? Surprising Migraine-Busting Drugs

Most migraine management is off-label, doctors say. Headache - Off-label use - Migraine - Health - Conditions and Diseases

After Fine, Botox Awaits F.D.A. Approval for Migraine

Allergan agreed to pay $600 million for Botox’s marketing getting ahead of approved uses. But the F.D.A. will soon decide on its effectiveness for chronic migraines.

Allergan sued over Botox off-label marketing

Allergan Inc. directors should be held liable for opening up the company, maker of wrinkle smoother Botox, to criminal sanctions and a $600 million settlement by allowing the drug to be marketed for unapproved uses, investors said in a lawsuit. Allergan's... Allergan - Off-label use - Marketing - Lawsuit - Food and Drug Administration

Hewlett-Packard, Citigroup, Barclays, Wal-Mart in Court News

Hewlett-Packard Co. said it sued former Chief Executive Officer Mark Hurd, who was hired by Oracle Corp. as a president, to force the executive to comply with agreements to protect confidential information.

Botox maker agrees to pay $600 million for misbranding

The Associated Press: "Allergan Inc., the maker of wrinkle-smoothing Botox, has agreed to pay $600 million to settle a yearslong federal investigation into its marketing of the top-selling, botulin-based drug. The Justice Department and the company said Wednesday in a statement it will plead guilty to one misdemeanor charge of 'misbranding,' in which the company's marketing led physicians to use ...